- Home
- RCKY vs NTHI Comparison
RCKY vs NTHI Comparison
Compare RCKY & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKY
- NTHI
- Stock Information
- Founded
- RCKY 1932
- NTHI 2008
- Country
- RCKY United States
- NTHI United States
- Employees
- RCKY N/A
- NTHI N/A
- Industry
- RCKY Shoe Manufacturing
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- RCKY Consumer Discretionary
- NTHI Health Care
- Exchange
- RCKY Nasdaq
- NTHI Nasdaq
- Market Cap
- RCKY 205.3M
- NTHI 195.5M
- IPO Year
- RCKY 1993
- NTHI N/A
- Fundamental
- Price
- RCKY $28.98
- NTHI $6.89
- Analyst Decision
- RCKY Buy
- NTHI
- Analyst Count
- RCKY 1
- NTHI 0
- Target Price
- RCKY $40.00
- NTHI N/A
- AVG Volume (30 Days)
- RCKY 108.0K
- NTHI 63.4K
- Earning Date
- RCKY 10-28-2025
- NTHI 11-14-2025
- Dividend Yield
- RCKY 2.14%
- NTHI N/A
- EPS Growth
- RCKY 53.66
- NTHI N/A
- EPS
- RCKY 2.74
- NTHI N/A
- Revenue
- RCKY $470,314,000.00
- NTHI $59,990.00
- Revenue This Year
- RCKY $7.09
- NTHI N/A
- Revenue Next Year
- RCKY $4.27
- NTHI N/A
- P/E Ratio
- RCKY $10.59
- NTHI N/A
- Revenue Growth
- RCKY 4.13
- NTHI N/A
- 52 Week Low
- RCKY $11.93
- NTHI $3.20
- 52 Week High
- RCKY $33.40
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- RCKY 50.12
- NTHI 34.32
- Support Level
- RCKY $28.74
- NTHI $8.93
- Resistance Level
- RCKY $31.42
- NTHI $9.57
- Average True Range (ATR)
- RCKY 1.45
- NTHI 1.11
- MACD
- RCKY -0.03
- NTHI -0.38
- Stochastic Oscillator
- RCKY 25.70
- NTHI 2.87
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).